What is RedHill Biopharma Ltd. (RDHL) stock price today?

RedHill Biopharma Ltd. (RDHL) is currently trading at $0.60, up 0.82% today.

What is RDHL P/E ratio?

RedHill Biopharma Ltd.'s P/E ratio is -0.30. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is RDHL return on equity (ROE)?

RedHill Biopharma Ltd.'s return on equity (ROE) is 0.00%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.

What is RedHill Biopharma Ltd.'s market cap?

RedHill Biopharma Ltd. has a market capitalization of $1.89M.

NASDAQ · Drug Manufacturers - Specialty & Generic

RedHill Biopharma Ltd. (RDHL) Stock

$0.60 +0.82% NASDAQ: RDHL Healthcare

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections.

Valuation

Metric	Value
Price	$0.60
Market Cap	$1.89M
P/E Ratio	-0.30
P/B Ratio	0.25
P/S Ratio	0.46
EPS (TTM)	$0.00
52-Week High	$2.79
52-Week Low	$0.58
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	0.00%
ROA	-16.31%
ROCE	-71.49%
Gross Margin	60.60%
Operating Margin	-107.33%
Net Margin	-101.32%
Debt/Equity	0.25
Current Ratio	0.34

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$86.0M	$62.0M	$7.0M	$8.0M	$0
Operating Profit	$-81.0M	$-43.0M	$13.0M	$-15.0M	$-8.0M
Net Profit	$-98.0M	$-72.0M	$24.0M	$-8.0M	$0
EPS	$-1000.00	$-600.00	$46.00	$-7.00	$0.00
Op Margin	-94.6%	-69.3%	193.4%	-181.7%	-2765.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$181.0M	$159.0M	$23.0M	$18.0M	$25.0M
Total Liabilities	$172.0M	$207.0M	$21.0M	$23.0M	$21.0M
Cash	$29.0M	$20.0M	$6.0M	$5.0M	$4.0M
Borrowings	$88.0M	$123.0M	$1.0M	$0	$1.0M

Latest News

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight PR Newswire · Jul 30, 2026 Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development PR Newswire · Jul 28, 2026 RedHill Biopharma Closes Private Placement MT Newswires · Jun 22, 2026 RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PR Newswire · Jun 22, 2026 RedHill Biopharma Announces Up To $19.4 Million Private Placement PR Newswire · Jun 18, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-65.0M	$-29.0M	$-36.0M	$-9.0M	$-10.0M
Investing Cash Flow	$-8.0M	$8.0M	$0	$0	$2.0M
Financing Cash Flow	$-3.0M	$-11.0M	$9.0M	$1.0M	$0
Net Cash Flow	$0	$-10.0M	$-14.0M	$-1.0M	$-1.0M
Free Cash Flow	$-65.0M	$-29.0M	$-36.0M	$-9.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.24
FCF Yield	-266.20%
Quick Ratio	0.34
Interest Coverage	-4.28
Return 1Y	-57.45%
Return 3Y	-97.14%
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held4.92%

Institutions Float Held4.92%

Institutional Holder	Shares	Report Date
Yorkville Advisors Global, LP	122,131	2026-06-30
Gagnon Securities, LLC	88,405	2026-06-30
Citadel Advisors Llc	20,673	2026-03-31
Xtx Topco Ltd	15,163	2026-03-31
Rhumbline Advisers	13,755	2026-06-30

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

RedHill Biopharma Ltd. is headquartered in IL.

RedHill Biopharma Ltd. (RDHL) stock trades at $0.60 with a market capitalization of $1.89M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.30, reflecting a net loss over the last twelve months, price-to-book of 0.25, price-to-sales of 0.46. Over the past 52 weeks the stock has ranged between $0.58 and $2.79, and currently trades 78.5% below its 52-week high.

On profitability, RedHill Biopharma Ltd. generates a return on equity (ROE) of 0.00%, return on capital employed of -71.49%, an operating margin of -107.33%, a net profit margin of -101.32%.

Official website: www.redhillbio.com